Oktay Kutluk, Bedoschi Giuliano, Pacheco Fernanda, Turan Volkan, Emirdar Volkan
Innovation Institute for Fertility and In Vitro Fertilization, New York, NY; Laboratory of Molecular Reproduction and Fertility Preservation, Obstetrics and Gynecology, New York Medical College, Valhalla, NY.
Innovation Institute for Fertility and In Vitro Fertilization, New York, NY; Laboratory of Molecular Reproduction and Fertility Preservation, Obstetrics and Gynecology, New York Medical College, Valhalla, NY; Faculdade de Medicina de Ribeirao Preto-Universidade de Sao Paulo, Ribeirao Preto, Sao Paulo, Brazil.
Am J Obstet Gynecol. 2016 Jan;214(1):94.e1-9. doi: 10.1016/j.ajog.2015.10.001. Epub 2015 Nov 18.
Ovarian tissue cryopreservation is an experimental fertility preservation method and the transplantation techniques are still evolving.
We attempted to improve the technique with the utility of a human decellularized extracellular tissue matrix (ECTM) scaffold, robot-assisted minimally invasive surgery, and perioperative pharmacological support.
We prospectively studied 2 subjects with hemophagocytic lymphohistiocytosis (patient A) and non-Hodgkin lymphoma (patient B) who underwent ovarian tissue cryopreservation at the age of 23 years, before receiving preconditioning chemotherapy for hematopoietic stem cell transplantation. Both experienced ovarian failure postchemotherapy and we transplanted ovarian cortical tissues to the contralateral menopausal ovary 7 and 12 years later, using a human ECTM scaffold and robotic assistance. The ECTM scaffold tissue compatibility was shown in preclinical studies. Patients also received estrogen supplementation and baby aspirin preoperatively to aid in the revascularization process.
Ovarian follicle development was observed approximately 10 (patient A) and 8 (patient B) weeks after ovarian tissue transplantation. Following 8 and 7 cycles of in vitro fertilization, 9 and 10 day-3 embryos were cryopreserved (patients A and B, respectively). While the baseline follicle-stimulating hormone (range 3.6-15.4 mIU/mL) levels near normalized by 7 months and remained steady postovarian transplantation in patient A, patient B showed improved but elevated follicle-stimulating hormone levels throughout (range 21-31 mIU/mL). Highest follicle yield was achieved 14 (8 follicles; patient A) and 11 (6 follicles; patient B) months postintervention. Patient A experienced a chemical pregnancy after the third frozen embryo transfer attempt. She then conceived following her first fresh in vitro fertilization embryo transfer and the pregnancy is currently ongoing. Patient B conceived after the first frozen embryo transfer attempt and delivered a healthy girl at term.
We report the first pregnancies after the minimally invasive transplantation of previously cryopreserved ovarian tissue with an ECTM scaffold. This approach seems to be associated with steady ovarian function after a follow-up of up to 2 years.
卵巢组织冷冻保存是一种实验性的生育力保存方法,其移植技术仍在不断发展。
我们试图通过使用人脱细胞细胞外组织基质(ECTM)支架、机器人辅助微创手术和围手术期药物支持来改进该技术。
我们前瞻性地研究了2名患有噬血细胞性淋巴组织细胞增生症(患者A)和非霍奇金淋巴瘤(患者B)的受试者,他们在23岁时接受造血干细胞移植的预处理化疗前进行了卵巢组织冷冻保存。两人化疗后均出现卵巢功能衰竭,我们在7年和12年后使用人ECTM支架和机器人辅助将卵巢皮质组织移植到对侧绝经卵巢。ECTM支架的组织相容性已在临床前研究中得到证实。患者术前还接受了雌激素补充和小剂量阿司匹林以辅助血管再生过程。
卵巢组织移植后约10周(患者A)和8周(患者B)观察到卵泡发育。经过8个和7个周期的体外受精后,分别冷冻保存了9个和10个第3天胚胎(患者A和患者B)。患者A在7个月时基础促卵泡激素水平(范围为3.6 - 15.4 mIU/mL)接近正常化,卵巢移植后保持稳定,而患者B的促卵泡激素水平虽有所改善但始终升高(范围为21 - 31 mIU/mL)。干预后14个月(8个卵泡;患者A)和11个月(6个卵泡;患者B)时获得最高卵泡产量。患者A在第三次冷冻胚胎移植尝试后出现化学妊娠。随后她在第一次新鲜体外受精胚胎移植后受孕,目前妊娠正在进行中。患者B在第一次冷冻胚胎移植尝试后受孕,并足月分娩一名健康女婴。
我们报告了首例使用ECTM支架对先前冷冻保存的卵巢组织进行微创移植后的妊娠情况。经过长达2年的随访,这种方法似乎与稳定的卵巢功能相关。